Please login to the form below

Not currently logged in
Email:
Password:

Teva's MS drug disappoints in trial

Teva Pharmaceutical Industries has said its oral MS drug laquinimod has failed to reach its primary endpoint in a phase III trial but the company still plans regulatory submissions in the EU and US

Teva Pharmaceutical Industries has said its oral multiple sclerosis (MS) drug laquinimod has failed to reach its primary endpoint in a phase III trial.

Compared to placebo, the therapy, which is being investigated for use in the treatment of relapsing-remitting multiple sclerosis (RRMS), did not reduce annual relapse rates of the disease.

However, Teva said there were dissimilarities in the baseline magnetic resonance imaging (MRI) characteristics of the study group receiving placebo and the study group receiving laquinimod, affecting the trial's results.

When adjusted, laquinimod demonstrated a significant reduction in relapse rate for the disease, as well as a reduced risk of disability progression and brain volume loss.

Teva said additional analyses of the study data are ongoing, and the company still has plans to submit the drug for approval in both the EU and US.

Professor Yitzhak Peterburg, Teva's group vice-president, Global Branded Products, said: "Teva remains committed to the clinical development of laquinimod and is confident that the drug could provide a unique option for the treatment of multiple sclerosis."

2nd August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics